Linked Life Data

17952603

Source:http://linkedlifedata.com/resource/pubmed/id/17952603

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17952603rdf:typepubmed:Citationlld:pubmed
pubmed-article:17952603lifeskim:mentionsumls-concept:C0020094lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C1882071lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0285558lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C1705328lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C1705341lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0538927lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0812228lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:17952603lifeskim:mentionsumls-concept:C1516044lld:lifeskim
pubmed-article:17952603pubmed:issue1lld:pubmed
pubmed-article:17952603pubmed:dateCreated2008-1-14lld:pubmed
pubmed-article:17952603pubmed:abstractTextAdult T-cell leukemia/lymphoma (ATLL) is an aggressive lymphoproliferative disease of very poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-I). Treatment of patients with ATLL using conventional chemotherapy has limited benefit because HTLV-I cells are refractory to most apoptosis-inducing agents. In this study, we report that Celecoxib induces cell death via the intrinsic mitochondrial pathway in HTLV-I transformed leukemia cells. Treatment with Celecoxib was associated with activation of Bax, decreased expression of Mcl-1, loss of the mitochondrial membrane potential and caspase-9-dependent apoptosis. These effects were independent from Bcl-2 and Bcl-xL. We also found that Celecoxib inhibited the Akt/GSK3 beta survival pathway in HTLV-I cells.lld:pubmed
pubmed-article:17952603pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:languageenglld:pubmed
pubmed-article:17952603pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:citationSubsetIMlld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17952603pubmed:statusMEDLINElld:pubmed
pubmed-article:17952603pubmed:monthJanlld:pubmed
pubmed-article:17952603pubmed:issn1360-8185lld:pubmed
pubmed-article:17952603pubmed:authorpubmed-author:TaylorJohn...lld:pubmed
pubmed-article:17952603pubmed:authorpubmed-author:NicotChristop...lld:pubmed
pubmed-article:17952603pubmed:authorpubmed-author:BrownMeganMlld:pubmed
pubmed-article:17952603pubmed:authorpubmed-author:Sinha-DattaUm...lld:pubmed
pubmed-article:17952603pubmed:issnTypePrintlld:pubmed
pubmed-article:17952603pubmed:volume13lld:pubmed
pubmed-article:17952603pubmed:ownerNLMlld:pubmed
pubmed-article:17952603pubmed:authorsCompleteYlld:pubmed
pubmed-article:17952603pubmed:pagination33-40lld:pubmed
pubmed-article:17952603pubmed:dateRevised2010-9-17lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:meshHeadingpubmed-meshheading:17952603...lld:pubmed
pubmed-article:17952603pubmed:year2008lld:pubmed
pubmed-article:17952603pubmed:articleTitleCelecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt.lld:pubmed
pubmed-article:17952603pubmed:affiliationDepartment of Microbiology, Immunology, and Molecular Genetics, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160, USA.lld:pubmed
pubmed-article:17952603pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17952603pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17952603lld:pubmed